This study is a prospective, multicenter study in which a serum sample will be collected at the day of starting neo adjuvant treatment in breast cancer patients
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
100
Collection of serum sample at the day of start of neo adjuvant treatment
Antoni van Leeuwenhoek
Amsterdam, North Holland, Netherlands
RECRUITINGpCR rate
Number of patients achieving a pathological complete response
Time frame: At 6 months
Radiological reduction on tumor size
Number of patients achieving a radiological response (CR, PR, SD) based on MRI after neo adjuvant treatment
Time frame: At 6 months
Pathological reduction on tumor size
Number of patients achieving a pathological response (CR, PR, SD) based on pathology report after neo adjuvant
Time frame: At 6 months
Residual cancer burden (RCB)
quantificaton of the residual disease after neoadjuvant therapy
Time frame: At 6 months
Distant recurrence free interval (DRFI)
Number of patients with distant recurrence
Time frame: Up to 120 months
Recurrence-free interval (RFI)
Number of patients with disease recurrence
Time frame: Up to 120 months
Overall survival (OS)
Number of patients alive or deceased
Time frame: Up to 120 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.